Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$127.59 - $203.08 $1.85 Million - $2.95 Million
-14,534 Reduced 61.77%
8,996 $1.82 Million
Q4 2022

Feb 13, 2023

BUY
$117.37 - $139.17 $148,942 - $176,606
1,269 Added 5.7%
23,530 $3.02 Million
Q3 2022

Nov 14, 2022

SELL
$135.27 - $180.11 $362,658 - $482,874
-2,681 Reduced 10.75%
22,261 $3.05 Million
Q2 2022

Aug 11, 2022

SELL
$108.81 - $179.33 $496,608 - $818,462
-4,564 Reduced 15.47%
24,942 $4.41 Million
Q1 2022

May 12, 2022

SELL
$119.61 - $157.85 $439,686 - $580,256
-3,676 Reduced 11.08%
29,506 $4.25 Million
Q4 2021

Feb 11, 2022

SELL
$142.57 - $190.86 $1.52 Million - $2.04 Million
-10,686 Reduced 24.36%
33,182 $5.13 Million
Q3 2021

Nov 12, 2021

SELL
$142.45 - $169.82 $9.32 Million - $11.1 Million
-65,452 Reduced 59.87%
43,868 $7.45 Million
Q2 2021

Aug 13, 2021

SELL
$135.08 - $161.1 $705,387 - $841,264
-5,222 Reduced 4.56%
109,320 $17.3 Million
Q1 2021

May 13, 2021

SELL
$137.51 - $190.8 $1.13 Million - $1.57 Million
-8,212 Reduced 6.69%
114,542 $15.9 Million
Q4 2020

Feb 10, 2021

SELL
$164.63 - $211.93 $3.47 Million - $4.46 Million
-21,062 Reduced 14.65%
122,754 $21.5 Million
Q3 2020

Nov 12, 2020

BUY
$145.95 - $195.69 $21 Million - $28.1 Million
143,816 New
143,816 $28.1 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.